Clinical Trial Update: Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study of azacitidine for injection in myelodysplastic syndrome patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• AZACITIDINE (AZACITIDINE)

Snippet

Sponsor: Bioniche Pharma USA LLC | Conditions: Myelodysplastic Syndrome | Phase 1 | Status: COMPLETED